The burden of systemic corticosteroid use in asthma management in Asia.
Asia
asthma
biological products
guideline adherence
policy
risk factors
steroids
Journal
Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
30
08
2022
accepted:
03
05
2023
medline:
21
7
2023
pubmed:
11
6
2023
entrez:
10
6
2023
Statut:
ppublish
Résumé
For most patients, asthma can be effectively managed using inhaled medications. However, patients who have severe and/or uncontrolled asthma, or who experience exacerbations, may require systemic corticosteroids (SCSs) to maintain asthma control. Although SCS are highly effective in this regard, even modest exposure to these medications can increase the risk for long-term, adverse health outcomes, such as type 2 diabetes, renal impairment, cardiovascular disease and overall mortality. Clinical and real-world data from studies investigating asthma severity, control and treatment practices around the globe have suggested that SCS are overused in asthma management, adding to the already substantial healthcare burden experienced by patients. Throughout Asia, although data on asthma severity, control and SCS usage are limited and vary widely among countries, available data strongly suggest a pattern of overuse consistent with the broader global trend. Coordinated changes at the patient, provider, institutional and policy levels, such as increasing disease awareness, promoting better adherence to treatment guidelines and increasing availability of safe and effective alternatives to SCS, are likely necessary to reduce the SCS burden for patients with asthma in Asia.
Substances chimiques
Adrenal Cortex Hormones
0
Anti-Asthmatic Agents
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
744-757Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.
Références
Collaborators GBDCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706.
Global Initiative for Asthma. Global strategy for asthma management and prevention. 2022.
Chastek B, Korrer S, Nagar SP, Albers F, Yancey S, Ortega H, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22(7):848-61.
Chung K, Kim K, Jung J, Oh K, Oh Y, Kim S, et al. Patterns and determinants of COPD-related healthcare utilization by severity of airway obstruction in Korea. BMC Pulm Med. 2014;14:27.
Hankin CS, Bronstone A, Wang Z, Small MB, Buck P. Estimated prevalence and economic burden of severe, uncontrolled asthma in the United States. J Allergy Clin Immunol. 2013;131(2):AB126.
Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896-902.
O'Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. Asthma progression and mortality: the role of inhaled corticosteroids. Eur Respir J. 2019;54(1):1900491.
Chang YL, Ko HK, Lu MS, Chou CL, Su KC, Hsu CC, et al. Independent risk factors for death in patients admitted for asthma exacerbation in Taiwan. NPJ Prim Care Respir Med. 2020;30(1):7.
Lee LK, Ramakrishnan K, Safioti G, Ariely R, Schatz M. Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma. BMJ Open Respir Res. 2020;7(1):e000534.
DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1260-344.
Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-59.
Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17(1):74.
Meghdadpour S, Lugogo NL. Medication regimens for managing stable asthma. Respir Care. 2018;63(6):759-72.
Maselli DJ, Peters JI. Medication regimens for managing acute asthma. Respir Care. 2018;63(6):783-96.
Menzies-Gow A, Canonica GW, Winders TA, Correia de Sousa J, Upham JW, Fink-Wagner AH. A charter to improve patient care in severe asthma. Adv Ther. 2018;35(10):1485-96.
Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46(3):622-39.
Schwartz E. Oral cortisone in intractable bronchial asthma; preliminary report. J Allergy. 1951;22(1):1-3.
Randolph TG, Rollins JP. The effect of cortisone on bronchial asthma. J Allergy. 1950;21(4):288-95.
Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev. 2001;(1):CD002178.
Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev. 2001;(1):CD000195.
Alangari AA. Corticosteroids in the treatment of acute asthma. Ann Thorac Med. 2014;9(4):187-92.
Kirkland SW, Cross E, Campbell S, Villa-Roel C, Rowe BH. Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for acute asthma. Cochrane Database Syst Rev. 2018;6(6):CD012629.
Dalal AA, Duh MS, Gozalo L, Robitaille MN, Albers F, Yancey S, et al. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm. 2016;22(7):833-47.
Ekstrom M, Nwaru BI, Hasvold P, Wiklund F, Telg G, Janson C. Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden. Allergy. 2019;74(11):2181-90.
Skov IR, Madsen H, Henriksen DP, Andersen JH, Pottegard A, Davidsen JR. Low dose oral corticosteroids in asthma associates with increased morbidity and mortality. Eur Respir J. 2022;60:2103054.
Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193-204.
Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216-29.
Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):110-116.e117.
Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703.
Al Efraij K, Johnson KM, Wiebe D, Sadatsafavi M, FitzGerald JM. A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. J Asthma. 2019;56(12):1334-46.
Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136(6):1488-95.
Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201(3):276-93.
Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1):51.
Agarwal R, Aggarwal AN, Dhooria S, Singh Sehgal I, Garg M, Saikia B, et al. A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2016;47(2):490-8.
Bloechliger M, Reinau D, Spoendlin J, Chang SC, Kuhlbusch K, Heaney LG, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19(1):75.
Pinto-Peñaranda LF, Echeverri-García AF, Velásquez-Franco CJ, Mesa-Navas MA, Muñoz-Grajales C, Zuluaga-Quintero M, et al. Daño de órgano en una cohorte de pacientes colombianos con lupus eritematoso sistémico: caracterización y factores asociados. Revista Colombiana de Reumatología. 2018;25(2):85-91.
Tran TN, King E, Sarkar R, Nan C, Rubino A, O'Leary C, et al. Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK. Eur Respir J. 2020;55(6):1902363.
Tran TN, MacLachlan S, Hicks W, Liu J, Chung Y, Zangrilli J, et al. Oral corticosteroid treatment patterns of patients in the United States with persistent asthma. J Allergy Clin Immunol Pract. 2021;9(1):338-346.e333.
Global Burden of Disease Collaborative Network. Global burden of disease study 2019 (GBD 2019) results Seattle, United States: Institute for Health Metrics and Evaluation (IHME). 2020 Available from: http://ghdx.healthdata.org/gbd-results-tool
Dhar R, Ip M, Kulkarni T, Kim SH, Perng DW, Yao X, et al. Challenges faced in managing adult asthma: a perspective from Asian countries. Respirology. 2020;25(12):1235-42.
Thompson PJ, Salvi S, Lin J, Cho YJ, Eng P, Abdul Manap R, et al. Insights, attitudes and perceptions about asthma and its treatment: findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong. Respirology. 2013;18(6):957-67.
Gold LS, Thompson P, Salvi S, Faruqi RA, Sullivan SD. Level of asthma control and health care utilization in Asia-Pacific countries. Respir Med. 2014;108(2):271-7.
Price D, David-Wang A, Cho SH, Ho JC, Jeong JW, Liam CK, et al. Time for a new language for asthma control: results from REALISE Asia. J Asthma Allergy. 2015;8:93-103.
Sato K, Ishii T, Kaise T. Burden of asthma in elderly Japanese patients: using hospital-based administrative claims data. Pulm Ther. 2020;6(2):247-60.
Nagase H, Adachi M, Matsunaga K, Yoshida A, Okoba T, Hayashi N, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020;69(1):53-60.
Lee E, Kim A, Ye YM, Choi SE, Park HS. Increasing prevalence and mortality of asthma with age in Korea, 2002-2015: a nationwide, population-based study. Allergy Asthma Immunol Res. 2020;12(3):467-84.
Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry. Chest. 2020;157(4):790-804.
Su N, Lin JT, Wang WY, Chen P, Zhou X, Wan HY, et al. A cross-section study of severe asthma in eight provinces of China. Zhonghua Nei Ke Za Zhi. 2016;55(12):917-21.
Kim DK, Park YB, Oh YM, Jung KS, Yoo JH, Yoo KH, et al. Korean Asthma Guideline 2014: summary of major updates to the Korean Asthma Guideline 2014. Tuberc Respir Dis (Seoul). 2016;79(3):111-20.
Nakamura Y, Tamaoki J, Nagase H, Yamaguchi M, Horiguchi T, Hozawa S, et al. Japanese guidelines for adult asthma 2020. Allergol Int. 2020;69(4):519-48.
Taiwan Asthma Guideline 2020. Available from: http://globalasthmanetwork.org/management/guides/taiwan/Taiwan_Asthma_guidelines_Adult%202020.pdf.
Agarwal R, Dhooria S, Aggarwal AN, Maturu VN, Sehgal IS, Muthu V, et al. Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India. 2015;32(Suppl 1):S3-S42.
Agency for Care Effectiveness (Singapore). ACE Clinical Guidances. 2021 Available from: https://www.ace-hta.gov.sg/healthcare-professionals/ace-clinical-guidances-(acgs)
Subspecialty Group of Respiratory Diseases, Society of Pediatrics, Chinese Medical Association, Editorial Board, Chinese Journal of Pediatrics. Guideline for the diagnosis and optimal management of asthma in children(2016). Zhonghua Er Ke Za Zhi. 2016;54(3):167-81.
Thai Asthma Council. Guidelines for diagnosis and treatment of asthma in Thailand-adult revised edition. 2020 Available from: https://www.tac.or.th/download/
Kim S, Kim J, Park SY, Um HY, Kim K, Kim Y, et al. Effect of pregnancy in asthma on health care use and perinatal outcomes. J Allergy Clin Immunol. 2015;136(5):1215-1223.e1-e6.
Choi JY, Yoon HK, Lee JH, Yoo KH, Kim BY, Bae HW, et al. Current status of asthma care in South Korea: nationwide the health insurance review and assessment service database. J Thorac Dis. 2017;9(9):3208-14.
Kim MH, Kim SH, Park SY, Ban GY, Kim JH, Jung JW, et al. Characteristics of adult severe refractory asthma in Korea analyzed from the severe asthma registry. Allergy Asthma Immunol Res. 2019;11(1):43-54.
Yu TH, Fu PK, Tung YC. Using medication utilization information to develop an asthma severity classification model. BMC Med Inform Decis Mak. 2017;17(1):177.
Shantakumar S, Ho YF, Tuan LW, Lin TM, Hershko AY, Chen YH. Epidemiological, clinical and economic burden of severe eosinophilic asthma in Taiwan: results from a large tertiary care hospital. Asian Pac J Allergy Immunol. 2020; https://doi.org/10.12932/ap-200220-0771
Salvi SS, Apte KK, Dhar R, Shetty P, Faruqi RA, Thompson PJ, et al. Asthma insights and management in India: lessons learnt from the Asia Pacific-Asthma Insights and Management (AP-AIM) Study. J Assoc Physicians India. 2015;63(9):36-43.
Singhal S, Mathew S. Evaluation of asthma management and control in adults in and around Pune City of Maharashtra. Res J Pharm Biol Chem Sci. 2020;11(1):104-108.
Lim GN, Allen JC, Tiew PY, Chen W, Koh MS. Healthcare utilization and health-related quality of life of severe asthma patients in Singapore. J Asthma. 2022;1-12:969-80.
Chan WL, Yang KP, Chao TF, Huang CC, Huang PH, Chen YC, et al. The association of asthma and atrial fibrillation-a nationwide population-based nested case-control study. Int J Cardiol. 2014;176(2):464-9.
Matsunaga K, Adachi M, Nagase H, Okoba T, Hayashi N, Tohda Y. Association of low-dosage systemic corticosteroid use with disease burden in asthma. NPJ Prim Care Respir Med. 2020;30(1):35.
Lee H, Ryu J, Nam E, Chung SJ, Yeo Y, Park DW, et al. Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study. Eur Respir J. 2019;54(5):1900804.
Fung FY, Linn YC. Steroids in traditional Chinese medicine: what is the evidence? Singapore Med J. 2017;58(3):115-20.
Chong YK, Ching CK, Ng SW, Mak TW. Corticosteroid adulteration in proprietary Chinese medicines: a recurring problem. Hong Kong Med J. 2015;21(5):411-6.
Jo EJ, Kim MY, Kim SH, Kwon YE, Park HK, Cho SH, et al. Implementation of asthma management guidelines and possible barriers in Korea. J Korean Med Sci. 2020;35(12):e72.
Choi JY, Yoon HK, Lee JH, Yoo KH, Kim BY, Bae HW, et al. Nationwide use of inhaled corticosteroids by south Korean asthma patients: an examination of the health insurance review and Service database. J Thorac Dis. 2018;10(9):5405-13.
Cho EY, Oh KJ, Rhee CK, Yoo KH, Kim BY, Bae HW, et al. Comparison of clinical characteristics and management of asthma by types of health care in South Korea. J Thorac Dis. 2018;10(6):3269-76.
Price D, Bjermer L, Bergin DA, Martinez R. Asthma referrals: a key component of asthma management that needs to be addressed. J Asthma Allergy. 2017;10:209-23.
Wong AJW, Chan JJ, Koh MS, Lian SWQ, Fook SMC, Ong MEH. Compliance with asthma guidelines and association with outcomes in the emergency department of a tertiary care teaching hospital. J Acute Med. 2018;8(3):119-26.
Salvi S, Madas S, Ghorpade D, Gadhave S, Barne M. Is underuse of inhaled corticosteroids for asthma in India contributing to 42% of global asthma deaths? Lung India. 2022;39(4):331-6.
Chan KP, Ko FWS, Ling KC, Cheung PS, Chan LV, Chan YH, et al. A territory-wide study on the factors associated with recurrent asthma exacerbations requiring hospitalization in Hong Kong. Immun Inflamm Dis. 2021;9(2):569-81.
Ko FW, Chan AM, Chan HS, Kong AY, Leung RC, Mok TY, et al. Are Hong Kong doctors following the global initiative for asthma guidelines: a questionnaire “survey on asthma management”? Hong Kong Med J. 2010;16(2):86-93. quiz 85 p following 893.
Zhong N, Lin J, Zheng J, Lai K, Xie C, Tang KJ, et al. Uncontrolled asthma and its risk factors in adult Chinese asthma patients. Ther Adv Respir Dis. 2016;10(6):507-17.
Kim BK, Park SY, Ban GY, Kim MA, Lee JH, An J, et al. Evaluation and management of difficult-to-treat and severe asthma: an expert opinion from the Korean academy of asthma, allergy and clinical immunology, the working group on severe asthma. Allergy Asthma Immunol Res. 2020;12(6):910-33.
Kim SH, Cho BL, Shin DW, Hwang SS, Lee H, Ahn EM, et al. The effect of asthma clinical guideline for adults on inhaled corticosteroids prescriptiontrend: a quasi-experimental study. J Korean Med Sci. 2015;30(8):1048-54.
Gill JM, Mainous AG 3rd, Nsereko M. The effect of continuity of care on emergency department use. Arch Fam Med. 2000;9(4):333-8.
van Loenen T, van den Berg MJ, Westert GP, Faber MJ. Organizational aspects of primary care related to avoidable hospitalization: a systematic review. Fam Pract. 2014;31(5):502-16.
Holder-Niles F, Haynes L, D'Couto H, Hehn RS, Graham DA, Wu AC, et al. Coordinated asthma program improves asthma outcomes in high-risk children. Clin Pediatr. 2017;56(10):934-41.
Chew SY, Leow JYL, Chan AKW, Chan JJ, Tan KBK, Aman B, et al. Improving asthma care with Asthma-COPD Afterhours Respiratory Nurse at Emergency (A-CARE). BMJ Open Qual. 2020;9(2):e000894.
Dornan L, Pinyopornpanish K, Jiraporncharoen W, Hashmi A, Dejkriengkraikul N, Angkurawaranon C. Utilisation of electronic health records for public health in Asia: a review of success factors and potential challenges. Biomed Res Int. 2019;2019:7341841.
Chiu KC, Boonsawat W, Cho SH, Cho YJ, Hsu JY, Liam CK, et al. Patients' beliefs and behaviors related to treatment adherence in patients with asthma requiring maintenance treatment in Asia. J Asthma. 2014;51(6):652-9.
Bourdin A, Shaw D, Menzies-Gow A, FitzGerald JM, Bleecker ER, Busse WW, et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. J Asthma. 2021;58(4):514-22.
Menzies-Gow A, Haslam T, Morris T, Gylvin L, Bleecker E, Nan C. P144 regional variation in OCS use for UK patients with asthma: heat map analysis. Thorax. 2019;74(Suppl 2):A169.
Kavanagh JE, Hearn AP, Dhariwal J, d'Ancona G, Douiri A, Roxas C, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496-506.
Menzies-Gow A, Gurnell M, Heaney LG, Corren J, Bel EH, Maspero J, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet. Respir Med. 2021;10:47-58.
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-97.
MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol. 2019;15(5):553-69.
Kang J, Cho YS, Choi DK, Lee JS, Oh YM, Lee SD, et al. Bronchial thermoplasty in patients with severe uncontrolled asthma: first Korean cases. J Korean Med Sci. 2019;34(15):e120.
Porsbjerg CM, Menzies-Gow AN, Tran TN, Murray RB, Unni B, Audrey Ang SL, et al. Global variability in administrative approval prescription criteria for biologic therapy in severe asthma. J Allergy Clin Immunol Pract. 2022;10:1202-1216.e23.
Beekman M, Hales J, Al-Ahmad M, Del Olmo R, Tan TL. Breaking the vicious circle-the asthma referral identifier (ReferID) tool. NPJ Prim Care Respir Med. 2022;32(1):40.
Liang Y, Wang D, Hua D, Liao H, Chen R. Short-term oral corticosteroids for initial treatment of moderate-to-severe persistent asthma: a double-blind, randomized, placebo-controlled trial. Respir Med. 2020;172:106126.
Zhang Y, He J, Yuan Y, Faramand A, Fang F, Ji H. Increased versus stable dose of inhaled corticosteroids for asthma exacerbations: a systematic review and meta-analysis. Clin Exp Allergy. 2019;49(10):1283-90.
Lovinsky-Desir S. The use of biologic therapies for the management of pediatric asthma. Pediatr Pulmonol. 2020;55(3):803-8.
Mitchell P, Leigh R. A drug safety review of treating eosinophilic asthma with monoclonal antibodies. Expert Opin Drug Saf. 2019;18(12):1161-70.
Clark NM, Feldman CH, Evans D, Levison MJ, Wasilewski Y, Mellins RB. The impact of health education on frequency and cost of health care use by low income children with asthma. J Allergy Clin Immunol. 1986;78(1 Pt 1):108-15.
Jani YH, Hirani B, Livingstone C. Evaluation of patients' knowledge about oral anticoagulant medicines and use of alert cards by community pharmacists. Int J Clin Pharm. 2021;43(1):203-11.
Asthma ReferID 2020. Available from: https://www.asthmareferid.com/.
Yii ACA, Tan JHY, Lapperre TS, Chan AKW, Low SY, Ong TH, et al. Long-term future risk of severe exacerbations: distinct 5-year trajectories of problematic asthma. Allergy. 2017;72(9):1398-405.
Kritikos V, Price D, Papi A, Infantino A, Stallberg B, Ryan D, et al. A multinational observational study identifying primary care patients at risk of overestimation of asthma control. NPJ Prim Care Respir Med. 2019;29(1):43.
Blakey J, Chung LP, McDonald VM, Ruane L, Gornall J, Barton C, et al. Oral corticosteroids stewardship for asthma in adults and adolescents: a position paper from the Thoracic Society of Australia and New Zealand. Respirology. 2021;26(12):1112-30.